Journal of Personalized Medicine (Feb 2021)

18F-FDG PET/CT Cannot Substitute Endoscopy in the Staging of Gastrointestinal Involvement in Mantle Cell Lymphoma. A Retrospective Multi-Center Cohort Analysis

  • Tetiana Skrypets,
  • Cristina Ferrari,
  • Luca Nassi,
  • Gloria Margiotta Casaluci,
  • Benedetta Puccini,
  • Lara Mannelli,
  • Kateryna Filonenko,
  • Irina Kryachok,
  • Felice Clemente,
  • Maria Carmela Vegliante,
  • Antonella Daniele,
  • Gianmauro Sacchetti,
  • Attilio Guarini,
  • Carla Minoia

DOI
https://doi.org/10.3390/jpm11020123
Journal volume & issue
Vol. 11, no. 2
p. 123

Abstract

Read online

The detection of gastrointestinal (GI) involvement in Mantle Cell Lymphoma is often underestimated and may have an impact on outcome and clinical management. We aimed to evaluate whether baseline 18F-FDG PET/CT presents comparable results to endoscopic biopsy in the diagnosis of GI localizations. In our retrospective cohort of 79 patients, sensitivity and specificity of 18F-FDG PET/CT were low for the stomach, with a fair concordance (k = 0.32), while higher concordance with pathologic results (k = 0.65) was detected in the colorectal tract. Thus, gastric biopsy remains helpful in the staging of MCL despite 18F-FDG PET/CT, while colonoscopy could be omitted in asymptomatic patients. The validation of our data in prospective cohorts is desirable

Keywords